These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Sulbenicillin and amikacin for febrile patients with cancer--with special reference to granulocytopenia].
    Author: Sampi K, Honda T, Hattori M.
    Journal: Gan To Kagaku Ryoho; 1983 Nov; 10(11):2377-81. PubMed ID: 6639099.
    Abstract:
    Between March 1978 and March 1983 ninety-four episodes of fever in 56 mainly granulocytopenic patients with cancer were treated empirically with a combination of sulbenicillin (5.0 g, every 6 hours) and amikacin (200 mg, every 6 hours) in Saitama Cancer Center. Profound granulocytopenia at the beginning of treatment (less than 100/mm3 of granulocytes) was present in 66% of the patients. Oral absorbable or nonabsorbable antibiotics were used in 59 febrile episodes. WBC transfusion was not given. The response rate for all documented infections was 75%, including 10 of 13 (77%) of bacteremias. The majority of infections with identified organisms were caused by aerobic gram-negative bacilli: the major gram-negative pathogens being Ps. aeruginosa (11 cases), Klebsiella spp. (7 cases), E. coli (7 cases) and Enterobacter spp. (7 cases). The response rate of gram-negative bacilliary infections was 74%. Pneumonia responded less satisfactorily than all other types of infection with the response rate of 20%. The response rate of 69% for profound persistent granulocytopenia (less than 100/mm3 of granulocytes without a rise during therapy) is higher than that of any other reports. The most common adverse effect was hepatotoxicity (19%), whereas oliguria or anuria occurred in two patients, by which they eventually expired.
    [Abstract] [Full Text] [Related] [New Search]